Boots gender pay gap data is 5%, less than a third of national average

Boots gender pay gap data is 5%, less than a third of national average

March 26 2018 Boots has published data on its gender pay gap, indicating the pay gap benefits...

Prescription levy to rise to £8.80 from April 1 in England

Prescription levy to rise to £8.80 from April 1 in England

February 28 2018 The single NHS prescription charge will increase 20p to £8.80 per item...

Minister admits less than half of Pharmacy Integration Fund has been spent

Minister admits less than half of Pharmacy Integration Fund has been spent

December 19 2017 There has been a “significant underspend” of funding committed to...

£1m funding for pharmacist prescribing clinics in Scotland confirmed for 2017-18

£1m funding for pharmacist prescribing clinics in Scotland confirmed for 2017-18

September 20 2017 The Scottish Government has confirmed that £1 million will be available...

  • Boots gender pay gap data is 5%, less than a third of national average

    Boots gender pay gap data is 5%, less than a third of national average

    Monday, 26 March 2018 12:43
  • Prescription levy to rise to £8.80 from April 1 in England

    Prescription levy to rise to £8.80 from April 1 in England

    Wednesday, 28 February 2018 19:20
  • Minister admits less than half of Pharmacy Integration Fund has been spent

    Minister admits less than half of Pharmacy Integration Fund has been spent

    Tuesday, 19 December 2017 09:45
  • £1m funding for pharmacist prescribing clinics in Scotland confirmed for 2017-18

    £1m funding for pharmacist prescribing clinics in Scotland confirmed for 2017-18

    Wednesday, 20 September 2017 14:00

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

Prescription-niFebruary 23 2015

Northern Ireland may reintroduce prescription charges for the general population to help fund access to ‘unapproved’ specialist medicines for patients with serious conditions.

Ideas being considered include bringing back the charge at £3 (the level it was when the prescription levy was removed in 2010), reviewing exemption categories, or introducing a small universal charge such as 30p, 50p or £1.

The proposals are part of a plan announced following the publication of the key findings of an evaluation into the Individual Funding Request process. This was “originally set up to provide access to unapproved specialist drugs where there is an agreed clinical need but where they are not routinely commissioned.”

Addressing the Northern Ireland Assembly, Health Minister Jim Wells said: “For some time now I have heard concerns raised by cancer patients and survivors, charities, the pharmaceutical industry and my colleagues in the Assembly that the existing process of providing access to new specialist medicines in Northern Ireland could be improved. This is why an evaluation into the current IFR process was necessary.”

Revising the IFR system will entail additional costs, said the minister. Coupled with additional “significant pressures across the entire medicines budget,” the minister added: “In view of the current financial position, and the need to invest in services such as the provision of new specialist drugs, I believe that this may be an appropriate time to reconsider the provision of free prescriptions in Northern Ireland.”

A consultation on the IFR and the reintroduction of the prescription levy is running for 12 weeks, and will include public consultation events.

Link:

NIDHSSSPS announcement    

IFR report and consultation    

Finance News

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...